A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Jun 2018
At a glance
- Drugs Eribulin (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Eisai Inc
- 04 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 17 May 2018 Planned End Date changed from 1 Jun 2019 to 30 Jun 2019.
- 17 May 2018 Planned primary completion date changed from 1 Jun 2018 to 30 Jun 2018.